


About Spherix Global Insights

Spherix is the world’s leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Eleven Areas

**Dermatology**

**Nephrology**

**Gastroenterology**

**Neuroscience**

**Rheumatology**

**Ophthalmology**

**Hematology**

**Oncology**

**Obesity**

**Respiratory**

**Market Access**

NEW
IN 2026!

This is a guide to the publications Spherix will produce in 2026. It is organized by therapeutic area, indication, and deliverable.

Type of Publications	
MARKET DYNAMIX	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.
REALTIME DYNAMIX	A US quarterly or EU4 +UK semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.
LAUNCH DYNAMIX	Published monthly, Launch Dynamix tracks a new brand’s first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmaskes real patient management patterns an uncovers the “why” behind treatment decisions.
PATIENT VOICE DYNAMIX	An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.
ACCOUNT MANAGEMENT DYNAMIX	Identify best practices to build high-performing national and regional account teams and benchmark your performance against competitors.
BENEFIT DESIGN DYNAMIX	Understand and predict market access trends and policy shifts affecting formulary management and reimbursement across commercial and government channels.
KEY ACCOUNT DYNAMIX	Gain strategic account intelligence on leading national and regional payers, IDNs, and specialty pharmacy accounts to support prioritization, engagement strategy, and planning.
PATIENT SERVICES DYNAMIX	Uncover best practices and comparative intelligence on indication and brand-level patient service programs and competencies.
SPECIAL TOPIX	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.
RAPIDPULSE DYNAMIX	Address focused, time-sensitive business questions using direct input from physicians, payers, and other healthcare decision-makers. Each engagement combines tailored methodology, therapeutic and market expertise, and AI-enabled execution.
For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com	

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.



BENEFIT DESIGN DYNAMIX

Introduction	Market & Stakeholder Landscape
Commercial Trends	- Pharmacy Benefits - Medical Benefits - Employer Trends & Influence
Government Trends	- Medicare Part D Benefits - Medicare Part B Benefits - Medicaid, Exchanges, & Other Government Programs

KEY ACCOUNT DYNAMIX

Comparative Assessments	- Leading Accounts - Blues & Regional Plans - Integrated Delivery Networks - Specialty Pharmacies
Account Profiles	- Leading Accounts (19 profiles) - Blues & Regional Plans (40 profiles) - Integrated Delivery Networks (50 profiles) - Specialty Pharmacies (16 profiles)

ACCOUNT MANAGEMENT DYNAMIX

Payer Benchmarking	- Medical Directors - Pharmacy Directors - Annual Review
IDN Benchmarking	- Medical Directors - Pharmacy Directors - Annual Review
Benchmarking by Specialty	Oncology⁺ Urology⁺

PATIENT SERVICES DYNAMIX

Autoimmune Market	- Patient Services Program Benchmarking - Patient Services Best Practices
Oncology Market	- Patient Services Program Benchmarking - Patient Services Best Practices
Orphan/Rare Market	- Patient Services Program Benchmarking - Patient Services Best Practices
Women's Health Market	- Patient Services Program Benchmarking - Patient Services Best Practices

SPECIAL TOPIX

- Pathways Influence in Oncology Access- Overall and by Tumor Type
- Government Pricing in Transition: MFP and MFN Dynamics⁺**
- Direct-to-Patient Access: New Pharmaceutical Channel Impact on Access⁺**
- AI-Enabled Market Access: Payer Decisions and Evidence Strategies⁺**
- PBM Market Evolution: Reform, Alternative Model, and Buyer Expectations⁺**

Key

BENEFIT DESIGN DYNAMIX	Explore commercial and government payer, physician and employer market experiences
KEY ACCOUNT DYNAMIX	Reports use detailed data from key decision-makers from leading national payers, regional payers, IDNs and specialty pharmacies.
ACCOUNT MANAGEMENT DYNAMIX	Reports use extensive data from medical directors and pharmacy directors at payers and IDNs.
PATIENT SERVICES DYNAMIX	Assesses physician, office staff, patient and caregiver experiences with patient service programs and attributes
SPECIAL TOPIX	Current events on specific interest areas Current events
RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

⁺Pending approvals and launch

⁺ **New in 2027** Publications may change due to factors such as FDA approval status and other market events



Alopecia Areata

MARKET DYNAMIX	Alopecia Areata, US
LAUNCH DYNAMIX	- Leqselvi (SUN Pharma) in Alopecia Areata, US Rinvoq (AbbVie) in Alopecia Areata, US**

Atopic Dermatitis

MARKET DYNAMIX	Atopic Dermatitis, JP
REALTIME DYNAMIX	- Atopic Dermatitis, US - Atopic Dermatitis, EU4 +UK
LAUNCH DYNAMIX	- Ebglyss (Eli Lilly) in Atopic Dermatitis, US - Nemluvio (Galderma) in Atopic Dermatitis, US - Vtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US
PATIENT CHART DYNAMIX	Atopic Dermatitis, US
PATIENT VOICE DYNAMIX	- Atopic Dermatitis, US - Atopic Dermatitis, EU4 +UK

Chronic Spontaneous Urticaria

MARKET DYNAMIX	Chronic Spontaneous Urticaria, US
LAUNCH DYNAMIX	Barzvolimab (Celldex) in CSU, US** - Dupixent (Sanofi/Regeneron) in CSU, US - Rhapsido (Novartis) in CSU, US
PATIENT CHART DYNAMIX	Chronic Spontaneous Urticaria, US

Prurigo Nodularis

MARKET DYNAMIX	Prurigo Nodularis, US
LAUNCH DYNAMIX	- Nemluvio (Galderma) in Prurigo Nodularis, US Povorcitinib (Incyte) in Prurigo Nodularis, US**

Plaque Psoriasis

REALTIME DYNAMIX	- Plaque Psoriasis, US - Plaque Psoriasis, EU4 +UK
LAUNCH DYNAMIX	Ichtyde (J&J) in Plaque Psoriasis, US
PATIENT VOICE DYNAMIX	Plaque Psoriasis, US
SPECIAL TOPIX	The Oral Opportunity in Plaque Psoriasis, US

Hidradenitis Suppurativa

MARKET DYNAMIX	Hidradenitis Suppurativa, US
LAUNCH DYNAMIX	- Bimzelx (UCB) in Hidradenitis Suppurativa, US Povorcitinib (Incyte) in Hidradenitis Suppurativa, US** Sonelokimab (MoonLake) in Hidradenitis Suppurativa, US** Rinvoq (AbbVie) in Hidradenitis Suppurativa, US**

Other Dermatology Indications

MARKET DYNAMIX	Vitiligo, US
LAUNCH DYNAMIX	Povorcitinib (Incyte) in Vitiligo, US** Rinvoq (AbbVie) in Vitiligo, US**
SPECIAL TOPIX	- Biologic Coordinators Across Dermatology, US Dermatologist Use of AI* Dermatology Patient Use of AI*

Dermatology-Adjacent Indications

MARKET DYNAMIX	- Asthma, US - Asthma, EU - Chronic Obstructive Pulmonary Disease, US - Chronic Obstructive Pulmonary Disease, EU
PATIENT VOICE DYNAMIX	Asthma, US* Chronic Obstructive Pulmonary Disease, US*

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas
RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch

* New in 2027



2026 & 2027 Gastroenterology Publications

Inflammatory Bowel Disease	
MARKET DYNAMIX	- Crohn's Disease, EU4 +UK (refresh) - Crohn's Disease, JP - Ulcerative Colitis, EU4 +UK (refresh) - Ulcerative Colitis, JP
REALTIME DYNAMIX	- Crohn's Disease, US - Ulcerative Colitis, US
LAUNCH DYNAMIX	- Tremfya (Janssen) in Crohn's Disease, US Obefazimod (Abivax) in Ulcerative Colitis, US** - OmvoH (Eli Lilly) in Crohn's Disease, US - Tremfya (Janssen) in Ulcerative Colitis, US
PATIENT CHART DYNAMIX	- Inflammatory Bowel Disease New Starts, US - Inflammatory Bowel Disease Switching, US - Inflammatory Bowel Disease Switching, EU4 +UK
SPECIAL TOPIX	- Biologic Coordinators in Gastroenterology, US - The Role of APPs in IBD
Obesity	
MARKET DYNAMIX	Obesity, US
LAUNCH DYNAMIX	- Wegovy Pill (Novo Nordisk) in Obesity, US - Foundayo (Eli Lilly) in Obesity, US - CagriSema (Novo Nordisk) in Obesity, US* Retatrutide (Eli Lilly) in Obesity, US**
PATIENT CHART DYNAMIX	Obesity, US *
PATIENT VOICE DYNAMIX	Obesity, US *

MASH	
MARKET DYNAMIX	- MASH, US - MASH, EU4 +UK
LAUNCH DYNAMIX	- Rezdiffra (Madriral) in MASH, US - Wegovy (Novo Nordisk) in MASH, US
PATIENT CHART DYNAMIX	MASH, US
PATIENT VOICE DYNAMIX	MASH, US *
SPECIAL TOPIX	MASH Screening and Management among PCPs and Endocrinologists, US

Other Gastroenterology Indications	
MARKET DYNAMIX	Autoimmune Hepatitis (AIH), US * - Celiac Disease, US (refresh) Chronic Hepatitis D Virus, US * - Eosinophilic Esophagitis, US - Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US (2025)
LAUNCH DYNAMIX	- Iqirvo (Ipsen) in Primary Biliary Cholangitis, US - Linavoy (Alfasigma) in Cholestatic Pruritus Among PBC Patients, US - Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US Lynavoy (GSK) in Cholestatic Pruritus Associated with Primary Biliary Cholangitis, US* * Saroglitazar (Zydus) in Primary Biliary Cholangitis, US* *
SPECIAL TOPIX	Gastroenterologist Use of AI * Gastroenterology Patient Use of AI * Primary Care Physician Use of AI *

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas
RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch

*** New in 2027** Publications may change due to factors such as FDA approval status and other market events



Bleeding Disorders

MARKET DYNAMIX	- Hemophilia A & B, US - Hemophilia A & B, EU4 +UK - Von Willebrand Disease, US
LAUNCH DYNAMIX	- Qfitlia (Sanofi) in Hemophilia A & B, US - Mim8 (Novo Nordisk) in Hemophilia A, US*
PATIENT CHART DYNAMIX	People with Bleeding Disorders
PATIENT VOICE DYNAMIX	People with Bleeding Disorders
SPECIAL TOPIX	Women, Girls, and people who have or have had the potential to menstruate (WGPPM) with Bleeding Disorders

Hemoglobinopathies

MARKET DYNAMIX	- Sickle Cell Disease, US - Thalassemia, US
LAUNCH DYNAMIX	- Aqvesme (Agiros Pharmaceuticals) in Thalassemia, US Aqvesme in SCD, US*⁺
PATIENT CHART DYNAMIX	- Sickle Cell Disease, US - Thalassemia, US
PATIENT VOICE DYNAMIX	Sickle Cell Disease, US
SPECIAL TOPIX	Primary Care in Sickle Cell Disease, US⁺

Paroxysmal Nocturnal Hemoglobinuria

MARKET DYNAMIX	Paroxysmal Nocturnal Hemoglobinuria, US
----------------	---

Other Benign Hematology Indications

MARKET DYNAMIX	- Warm Autoimmune Hemolytic Anemia (w-AIHA), US - Immune Thrombocytopenic Purpura (ITP), US
LAUNCH DYNAMIX	- Nipocalimab (J&J) in w-AIHA, US* - Wayrilz (Sanofi) in ITP, US
PATIENT CHART DYNAMIX	Immune Thrombocytopenic Purpura (ITP), US⁺

Other Hematology Indications

SPECIAL TOPIX	- AI in Hematology and Oncology, US (2026) Gene Therapy, US⁺ Hematologist Use of AI⁺
---------------	--

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas
RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions



2026 & 2027 Nephrology Publications

Glomerular Disease		CKD, Dialysis & Transplant	
MARKET DYNAMIX	- Alport Syndrome, US - FSGS, US - Membranous Nephropathy, US APOL-1 Mediated Kidney Disease, US * IgAN, Brazil * IgAN, Canada * IgAN, China * IgAN, Japan * IgAN, KSA * IgAN, UAE *	MARKET DYNAMIX	Transplant/AMR, US * AD-PKD, US * CKM, US * Dialysis, US (covers Devices and Machines, HP, and SHPT) *
REALTIME DYNAMIX	- IgAN, US - IgAN, EU4+UK	REALTIME DYNAMIX	Dialysis, US (Nephrologist; Renal Dietitians)
LAUNCH DYNAMIX	- Filspari (Travere) in FSGS, US - Voyxact (Otsuka) in IgAN, US - Trutakna (Vera) in IgAN, US Povetacicept (Vertex) in IgAN, US ** Ultomiris (Alexion) in IgAN, US ** Gazyva (Genentech) in pMN, US **	LAUNCH DYNAMIX	OLC (Unicycive) in Hyperphosphatemia, US **
PATIENT CHART DYNAMIX	- FSGS, US - IgAN, US - IgAN, China - IgAN, EU4+UK - IgAN, Japan IgAN, Brazil * APOL-1 Mediated Kidney Disease, US * Membranous Nephropathy, US *	PATIENT CHART DYNAMIX	Transplant/AMR, US * - Chronic Kidney Disease, Non-Dialysis, Nephrologist, US - Chronic Kidney Disease, Non-Dialysis, PCP, US - Dialysis, US
PATIENT VOICE DYNAMIX	- IgAN, US FSGS, US *	PATIENT VOICE DYNAMIX	Chronic Kidney Disease, US
SPECIAL TOPIX	ASN Feedback: Focus on Glomerular Disease	SPECIAL TOPIX	Biologic Coordinators & Access Facilitators in Nephrology * Decision-Making in AI (Nephrologists, PCPs) * Nephrology Pipeline, US * Nephrologist Use of AI * Primary Care Physician Use of AI *

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas
	RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch

* New in 2027

Publications may change due to factors such as FDA approval status and other market events



2026 & 2027 Neuroscience Publications

Alzheimer's Disease		Generalized Myasthenia Gravis	
MARKET DYNAMIX	Alzheimer's Disease, US	REALTIME DYNAMIX	- Generalized Myasthenia Gravis, US - Generalized Myasthenia Gravis, EU4 +UK
PATIENT CHART DYNAMIX	Alzheimer's Disease, US	LAUNCH DYNAMIX	- Uplizna, (Amgen) in Generalized Myasthenia Gravis, US - Imaavy, (J&J) in Generalized Myasthenia Gravis, US Cemdisiran, (Regeneron) in Generalized Myasthenia Gravis, US** Gefurulumab, (Alexion/AZ) in Generalized Myasthenia Gravis, US** Descartes-08 (Cartesian) in Generalized Myasthenia Gravis, US**
Migraine		PATIENT CHART DYNAMIX	- Generalized Myasthenia Gravis, US - Generalized Myasthenia Gravis, EU4 +UK
MARKET DYNAMIX	Menstrual Migraine, US *	PATIENT VOICE DYNAMIX	Generalized Myasthenia Gravis, US
LAUNCH DYNAMIX	Dysport (Ipsen) in Migraine, US**	SPECIAL TOPIX	- Biologic Coordinators in Generalized Myasthenia Gravis Ocular Myasthenia Gravis**
REALTIME DYNAMIX	- Migraine (Neurologists & PCPs), US Migraine, EU4 + UK *	Duchenne Muscular Dystrophy	
PATIENT CHART DYNAMIX	Migraine, US * Migraine, EU4 + UK *	MARKET DYNAMIX	Duchenne Muscular Dystrophy, US *
PATIENT VOICE DYNAMIX	Migraine, US *	LAUNCH DYNAMIX	Deramiciol (Capricor Therapeutics) in Duchenne Muscular Dystrophy, US** Z-rostudirsen / DYNE-251 (Dyne Therapeutics) in Duchenne Muscular Dystrophy, US** SGT-003 (Solid Biosciences) in Duchenne Muscular Dystrophy, US** RGX-202 (REGENXBIO) in Duchenne Muscular Dystrophy, US**
Multiple Sclerosis		Psychiatric Indications	
MARKET DYNAMIX	Multiple Sclerosis, US	MARKET DYNAMIX	- Schizophrenia, US Major Depressive Disorder, US * Bipolar Disorder, US *
LAUNCH DYNAMIX	Fenebrutinib (Genentech) in Multiple Sclerosis, US** Remibrutinib (Novartis) in Multiple Sclerosis, US**	SPECIAL TOPIX	Behavioral and Psychiatric Symptoms in Alzheimer's Disease, US
PATIENT CHART DYNAMIX	Multiple Sclerosis, US	Other Neuroscience Indications	
SPECIAL TOPIX	- Post-ACTRIMS/ECTRIMS Coverage Biologic Coordinators in Multiple Sclerosis, US *	MARKET DYNAMIX	- Chronic Inflammatory Demyelinating Polyneuropathy, US Parkinson's Disease, US * Narcolepsy/Sleep Disorders, US * Rett Syndrome, US * Rare Neuro-Immune Indications, US *
Other Neuroscience Indications		LAUNCH DYNAMIX	Tavapadon (AbbVie) in Parkinson's Disease, US**
MARKET DYNAMIX	- Chronic Inflammatory Demyelinating Polyneuropathy, US Parkinson's Disease, US * Narcolepsy/Sleep Disorders, US * Rett Syndrome, US * Rare Neuro-Immune Indications, US *	SPECIAL TOPIX	- Cell Therapies in Neuro-Immune Indications Neurologist Use of AI * Primary Care Physician Use of AI *
LAUNCH DYNAMIX	Tavapadon (AbbVie) in Parkinson's Disease, US**		
SPECIAL TOPIX	- Cell Therapies in Neuro-Immune Indications Neurologist Use of AI * Primary Care Physician Use of AI *		

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas
RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch

* New in 2027

Publications may change due to factors such as FDA approval status and other market events



MASH	
MARKET DYNAMIX	- MASH, US - MASH, EU4 +UK
LAUNCH DYNAMIX	- Rezdiffra (Madrigal) in MASH, US - Wegovy (Novo Nordisk) in MASH, US
PATIENT CHART DYNAMIX	MASH, US *
SPECIAL TOPIX	MASH Screening and Management among PCPs and Endocrinologists, US

CKD, Non-Dialysis	
PATIENT CHART DYNAMIX	- Chronic Kidney Disease, Non-Dialysis, Nephrologist, US - Chronic Kidney Disease, Non-Dialysis, PCP, US
PATIENT VOICE DYNAMIX	Chronic Kidney Disease, US

Obesity	
MARKET DYNAMIX	Obesity, US
LAUNCH DYNAMIX	- Wegovy Pill (Novo Nordisk) in Obesity, US - Foundayo (Eli Lilly) in Obesity, US - CagriSema (Novo Nordisk) in Obesity, US* Retatrutide (Eli Lilly) in Obesity, US* *
PATIENT CHART DYNAMIX	Obesity, US *
PATIENT VOICE DYNAMIX	Obesity, US *

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas
	RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch



2026 & 2027 Oncology Publications

Hematologic Oncology		Medical Oncology	
Acute Myeloid Leukemia		Solid Tumors	
MARKET DYNAMIX	Acute Myeloid Leukemia, US	REALTIME DYNAMIX	- PD-1 Inhibition in Solid Tumors, US RAS-Driven Solid Tumors, US*
LAUNCH DYNAMIX	- Komzifti (Kura) in Acute Myeloid Leukemia, US - Revuforj (Syndax) in Acute Myeloid Leukemia, US		
B-Cell Malignancies		Other Oncology Indications	
MARKET DYNAMIX	- B-Cell Malignancies, US - Large B-Cell Lymphoma, EU	SPECIAL TOPIX	- AI in Hematology and Oncology, US (2026) Cell Therapy in Solid Tumors, US* Coordination between Community + Academic Physicians in Advanced Oncology, US* Oncology Vaccines, US* Oncologist Use of AI*
PATIENT CHART DYNAMIX	- Large B-Cell Lymphoma, US - Chronic Lymphocytic Leukemia, US		
PATIENT VOICE DYNAMIX	B-Cell Malignancies, US		
Multiple Myeloma			
MARKET DYNAMIX	Multiple Myeloma, EU4 +UK		
REALTIME DYNAMIX	Multiple Myeloma, US		
LAUNCH DYNAMIX	- Lynozytic (Regeneron) in Multiple Myeloma, US - Blenrep (GSK) in Multiple Myeloma, US - Darzalex Faspro (J&J) in High-Risk Smoldering Multiple Myeloma, US Anito-cel (Gilead/Kite) in Multiple Myeloma, US* Mezigdomide (Bristol Myers Squibb) in Multiple Myeloma, US*		
PATIENT CHART DYNAMIX	Multiple Myeloma, US		
PATIENT VOICE DYNAMIX	Multiple Myeloma, US		
SPECIAL TOPIX	High-Risk Smoldering Multiple Myeloma, US		
Myeloproliferative Neoplasms (MPN)			
MARKET DYNAMIX	Myeloproliferative Neoplasms, US		

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas
	RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch



Diabetic Macular Edema & Neovascular Age-Related Macular Degeneration

REALTIME DYNAMIX	Diabetic Macular Edema & Age-Related Macular Degeneration, US
LAUNCH DYNAMIX	Axpaxli (Ocular Therapeutix) in Neovascular Age-Related Macular Degeneration, US* + Zenkuda (Kodiak Sciences) in Neovascular Age-Related Macular Degeneration & Diabetic Retinopathy, US* +
PATIENT CHART DYNAMIX	Age-Related Macular Degeneration, US

Other Ophthalmology Indications

MARKET DYNAMIX	- Diabetic Retinopathy, US Glaucoma, US + Geographic Atrophy, US + Thyroid Eye Disease (TED), US +
LAUNCH DYNAMIX	- Lumvoa, (Viridian) in Thyroid Eye Disease (TED), US Enspryng (Genentech) in Thyroid Eye Disease (TED), US* +
SPECIAL TOPIX	- Gene Therapies in Retina, US Ophthalmologist Use of AI +

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas
RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch

+ New in 2027

Publications may change due to factors such as FDA approval status and other market events



Asthma	
MARKET DYNAMIX	- Asthma, US - Asthma, EU
PATIENT VOICE DYNAMIX	Asthma, US *

Chronic Obstructive Pulmonary Disease	
MARKET DYNAMIX	- Chronic Obstructive Pulmonary Disease, US - Chronic Obstructive Pulmonary Disease, EU
PATIENT VOICE DYNAMIX	Chronic Obstructive Pulmonary Disease, US *

Interstitial Lung Disease	
SPECIAL TOPIX	ILD in Rheumatology, US (2026)

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas
	RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch



2026 & 2027 Rheumatology Publications



Spondyloarthritis (AS, nr-AxSpA, and PsA)	
MARKET DYNAMIX	• Ankylosing Spondylitis & nr-AxSpA, US * • Ankylosing Spondylitis & nr-AxSpA, EU4 +UK (2025) • Psoriatic Arthritis, EU4 +UK (2025)
REALTIME DYNAMIX	• Psoriatic Arthritis, US
LAUNCH DYNAMIX	• Bimzelx (UCB) in AS & nr-AxSpA, US • Bimzelx (UCB) in Psoriatic Arthritis, US • Sotyktu (BMS) in Psoriatic Arthritis, US • Ilumya (Sun) in Psoriatic Arthritis, US *
PATIENT VOICE DYNAMIX	• Psoriatic Arthritis, US
Other Rheumatology Indications	
MARKET DYNAMIX	• Idiopathic Inflammatory Myopathies, US (2026 Refresh) • IgG4-RD, US * • Rheumatoid Arthritis, US (2026 Refresh) • Rheumatoid Arthritis, EU4 +UK (2025) • Sjogren's Disease, US (2026 Refresh) • Systemic Sclerosis, US
LAUNCH DYNAMIX	• Rinvoq (AbbVie) in Giant Cell Arteritis, US • Cosentyx (Novartis) in PMR, US* • Brepocitinib (Priovant Therapeutics) in Dermatomyositis , US* • Ianalumab (Novartis) in Sjogren's Disease, US * * • Obexelimab (Zenas) in IgG4-RD, US * * • Vyvgart Hytrulo (argenx) in IIM, US * *
PATIENT VOICE DYNAMIX	• Systemic Sclerosis, US • Sjogren's Disease, US *
SPECIAL TOPIX	• Biologic Coordinators Across Rheumatology, US • Cell Therapy in Rheumatology, US • ILD in Rheumatology, US (2026) • Business of Rheumatology, US * • Rheumatologist Use of AI * • Rheumatology Patient Use of AI *

Lupus	
MARKET DYNAMIX	• Cutaneous Lupus, US (2026) • Systemic Lupus Erythematosus Pipeline, US • Systemic Lupus Erythematosus, EU4 +UK • Systemic Lupus Erythematosus/ Lupus Nephritis, China *
REALTIME DYNAMIX	• Systemic Lupus Erythematosus/ Lupus Nephritis, US • Systemic Lupus Erythematosus/Lupus Nephritis, EU4 +UK • Systemic Lupus Erythematosus/Lupus Nephritis, Brazil * • Systemic Lupus Erythematosus/Lupus Nephritis, Canada *
LAUNCH DYNAMIX	• Gazyva (Genentech) in Lupus Nephritis, US • Saphnelo SC (AstraZeneca) in Systemic Lupus Erythematosus, US • Gazyva (Genentech) in Systemic Lupus Erythematosus, US * * • Litifilimab (Biogen) in Systemic Lupus Erythematosus, US * * • Sotyktu (BMS) in Systemic Lupus Erythematosus, US * * • Rinvoq (AbbVie) in Systemic Lupus Erythematosus, US * *
PATIENT CHART DYNAMIX	• Cutaneous Lupus, US • Lupus Nephritis, US • Systemic Lupus Erythematosus , US • Systemic Lupus Erythematosus & Lupus Nephritis, EU4 +UK
PATIENT VOICE DYNAMIX	• Systemic Lupus Erythematosus & Lupus Nephritis, US

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU4 +UK) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas
	RAPIDPULSE DYNAMIX	Rapid market intelligence for time-sensitive decisions

*Pending approvals and launch

* New in 2027

Visit The Spherix Portal



Looking for more? Visit the Spherix Portal

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

Create your free account at
www.clientportal.spherixglobalinsights.com